

Recurrence of juvenile dermatomyositis 8 years after remission



Ken Muramatsu, MD,^{a,b} Hideyuki Ujiie, MD, PhD,^a Mayumi Yokozeki, MD,^b
Ichiro Tsukinaga, MD,^b Mai Ito, MD,^c Takaaki Shikano, MD,^c Akira Suzuki, MD, PhD,^d
Yusuke Tozawa, MD,^e and Ichiro Kobayashi, MD, PhD^{c,e}
Sapporo, Japan

Key word: juvenile dermatomyositis.

INTRODUCTION

Juvenile dermatomyositis (JDM) is a chronic inflammatory disease characterized by typical skin lesions and muscle weakness, which occurs in children and adolescents younger than 16 years.¹ JDM is classified into 3 clinical types according to the posttreatment course: (1) monocyclic, in which there is one episode with permanent remission within 2 years after diagnosis; (2) polycyclic, with multiple relapses within 2 years; and (3) continuous, with pathologic states persisting for more than 2 years.² Early treatment with prednisolone is suggested to limit the disorder to the monocyclic course.³ Only 2 case reports in which monocyclic JDM recurred more than 3 years after remission have been described in the English-language literature.^{4,5} Of these 2 reported cases, 1 patient had no initial treatment and the other had oral prednisolone (PSL) alone.^{4,5} Recently a well-designed randomized, controlled trial found that aggressive therapeutic approaches, such as PSL plus methotrexate (MTX) after methylprednisolone (mPSL) pulse therapy, outperform PSL monotherapy after mPSL pulse therapy with respect to clinical remission, treatment failure, and discontinuation of PSL.⁶ Here we present a case of monocyclic JDM that recurred 8 years after remission despite initial treatment with PSL plus MTX after mPSL pulse therapy.

CASE REPORT

A 4-year-old Japanese boy presented with eruptions on the face, ears, elbows, and knees and with

Abbreviations used:

CDASI:	Cutaneous Dermatomyositis Area and Severity Index
JDM:	juvenile dermatomyositis
MTX:	methotrexate
mPSL:	methylprednisolone
PSL:	prednisolone

muscular weakness. Physical examination found erythema on the cheeks and ears, keratotic papules and purplish erythema on the dorsa of the hands, and scaly erythema on the knees (Fig 1, A and B). This patient had no symptoms of dysphonia. Cutaneous Dermatomyositis Area and Severity Index (CDASI) was 8. The histopathology of the left knee showed vacuolar changes in the epidermis, deposition of mucin, pigment incontinence, and infiltration of lymphocytes in the papillary dermis (Fig 2, A). Biochemical examination found elevated levels of creatine kinase 425 IU/L (normal range, 12–170 IU/L) and aldolase 19.0 IU/L (2.7–7.5 IU/L). Antinuclear antibody and anti-Jo-1 antibody were negative. Magnetic resonance imaging (T2) found diffuse high-intensity areas in the proximal muscles of the extremities, which suggests edema caused by inflammation (Fig 2, B). Based on the clinical, histopathologic, and radiologic findings, the diagnosis of JDM was made. According to the recommended regimen at that time,⁷ the patient was treated with 2 courses of mPSL pulse therapy (30 mg/kg/d for 3 consecutive days per course) followed by

From the Departments of Dermatology^a and Pediatrics,^e Hokkaido University Graduate School of Medicine and the Departments of Dermatology^b and Pathology^d and Center for Pediatric Allergy and Rheumatology,^c KKR Sapporo Medical Center.

Funding sources: None.

Conflicts of interest: None declared.

Correspondence to: Hideyuki Ujiie, MD, PhD, Assistant Professor, Department of Dermatology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-838, Japan. E-mail: h-ujie@med.hokudai.ac.jp.

JAAD Case Reports 2017;3:29-32.

2352-5126

© 2016 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

<http://dx.doi.org/10.1016/j.jdc.2016.10.003>



Fig 1. Erythema on the cheeks and ears at initial onset (4 years old) (**A**) and at relapse (12 years old) (**C**). Keratotic papules and purplish erythema on the dorsal of the left hand at initial onset (**B**) and at relapse (**D**).

combination therapy with PSL (1 mg/kg/d) and MTX (0.4 mg/kg/wk), both of which were tapered out in 6 months. Both clinical and biochemical remission was achieved and persisted for 8 years, suggesting a monocyclic course.

At 12 years of age, the patient presented to us with similar symptoms affecting the skin and proximal muscles but without preceding infectious episodes within the previous 3 months (**Fig 1, C and D**). Elevated levels of aspartate aminotransferase, 104 IU/L (0–35 IU/L); alanine aminotransferase, 53 IU/L (0–35 IU/L); lactate dehydrogenase, 506 IU/L (80–200 IU/L); creatine kinase, 1930 IU/L (12–170 IU/L), and aldolase 28.6 IU/L (2.7–7.5 IU/L) were observed. Antinuclear, anti-Jo-1, anti-Sm, anti-SS-A, anti-SS-B and anti-RNP antibodies were all negative.

The IgM class of antiparvovirus B19 antibodies was not detected. Computed tomography scans showed neither interstitial pneumonia nor visceral malignancy. The clinical, histopathologic, and radiologic findings were virtually identical to those observed 8 years before (**Fig 2, C and D**). These findings confirmed the diagnosis of JDM relapse. Both the skin condition and muscle strength improved with 2 courses of mPSL pulse therapy (1 g/d for 3 consecutive days per course) followed by PSL (0.78 mg/kg/d) and MTX (0.20 mg/kg/wk). Serum levels of muscle-derived enzymes also returned to normal ranges. However, when the PSL dose was decreased to 0.29 mg/kg/d, elevation of muscle-derived enzymes and muscle weakness recurred, accompanied by pseudohypertrophy of the gastrocnemius

Download English Version:

<https://daneshyari.com/en/article/5646244>

Download Persian Version:

<https://daneshyari.com/article/5646244>

[Daneshyari.com](https://daneshyari.com)